We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics


Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App

New Panel Quickly and Accurately Identifies 16 Common Gastrointestinal Pathogens

By LabMedica International staff writers
Posted on 06 Jun 2024
Print article
Image: The QIAstat-Dx Gastrointestinal Panel 2 has received U.S. FDA clearance for use in clinical settings (Photo courtesy of QIAGEN)
Image: The QIAstat-Dx Gastrointestinal Panel 2 has received U.S. FDA clearance for use in clinical settings (Photo courtesy of QIAGEN)

Gastrointestinal (GI) infections significantly contribute to infectious disease cases globally, particularly among young children. The symptoms of GI infections, such as diarrhea, nausea, vomiting, and abdominal pain, are typically nonspecific and overlapping, making it challenging to identify the exact causative pathogens, which could be bacteria, viruses, or parasites. Accurate diagnosis is crucial for providing timely and effective care. Traditional methods for diagnosing GI infections often involve multiple time-consuming tests that require specialized expertise, such as stool culture and microscopy. These tests can take 1–2 days or more to yield results, and the diagnostic yield is often low. Traditional microbiological testing may need samples to be incubated for at least 24 hours and up to 10 days. In contrast, a multiplex syndromic panel test can deliver results for multiple bacterial, viral, and parasitic pathogens in about an hour. This faster and more sensitive method can significantly improve diagnostic yield, enhance patient management, and support antimicrobial stewardship efforts. An innovative molecular test now offers rapid and accurate identification of up to 16 common GI pathogens, generating results in approximately one hour using real-time PCR technology.

QIAGEN’s (Venlo, Netherlands) QIAstat-Dx Gastrointestinal Panel 2 aims to enhance the accuracy and efficiency of GI diagnosis. This panel can simultaneously detect up to 16 clinically relevant bacterial, viral, and parasitic pathogens causing most GI infections in about an hour. It utilizes QIAstat-Dx’s real-time PCR technology to quickly amplify multiple genetic targets. The software interprets signals from the reaction and provides positive or negative results for each pathogen. Additionally, QIAstat-Dx offers easy-to-view cycle threshold (Ct) values and amplification curves, providing extra insights not available with end-point PCR or other techniques.

QIAGEN has launched the QIAstat-Dx Gastrointestinal Panel 2 in the U.S., following FDA clearance for its clinical use. Acute infectious gastroenteritis is a common cause of hospitalizations and outpatient visits in the U.S., with an estimated 180 million cases annually. The U.S. launch will help healthcare providers diagnose and treat patients quickly and accurately, allowing for rapid isolation of those at risk of spreading infections and earlier identification of negative cases. This can reduce unnecessary testing and treatment costs for the U.S. healthcare system and patients. The new panel expands QIAGEN’s U.S. syndromic testing menu, complementing the QIAstat-Dx Respiratory Panel Plus, which can identify 21 pathogens causing respiratory infections from viral and bacterial sources. Both panels are available as cost-efficient, single-use cartridges that easily fit into the QIAstat-Dx Analyzer 1.0. These cartridges contain all necessary reagents, allowing for setup in less than a minute without the need for precision pipetting.

“The QIAstat-Dx Gastrointestinal Panel 2 allows medical professionals to identify which GI pathogen they are dealing with quickly,” said Fernando Beils, Senior Vice President and Head of the Molecular Diagnostics Business Area at QIAGEN. “This is QIAGEN’s answer to two major problems in treating GI infections: diagnosis of overlapping symptoms and laborious testing methods.”

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article


Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells (Photo courtesy of Rocky Mountain Laboratories, NIAID, NIH)

AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.